Extended Data Fig. 4: In vivo AAL pharmacokinetics and biodistribution.
a. Ketamine quantification in blood samples collected at different timepoints after 1 mg/kg body weight intravenous bolus injection of free, unencapsulated ketamine-HCl or S5-KL (n = 4 adult rats each) shows differential blood clearance with S5-KL compared to free ketamine and its major metabolites norketamine and hydroxynorketamine (Quantification in Extended Data Table 3). b. Ketamine quantification in different organs after 60 min following 1.5 mg/kg body weight intravenous bolus injection of free ketamine or S5-KL shows higher solid organ drug accumulation with ketamine-HCl compared to the ketamine-loaded AAL (S5-KL; n = 4 adult rats each). No significant differences of the metabolite solid organ uptake was noted between the formulations. Data presented as mean ± SD. Comparisons between multiple groups performed by one way analysis of variance (ANOVA), ns = non-significant, *p < 0.05, **p < 0.01 and ***p < 0.001.
